Discovery of novel flavonoid-based CDK9 degraders for prostate cancer treatment via a PROTAC strategy-Reference-Cited by-同舟云学术

Discovery of novel flavonoid-based CDK9 degraders for prostate cancer treatment via a PROTAC strategy

Published:2023-11 Issue: Volume:260 Page:115774
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Wu Tizhi,Zhang Zhiming,Gong Guangyue,Du Zekun,Xu Yifan,Yu Sixian,Ma Feihai,Zhang Xuan,Wang Yuxiao,Chen Haoming,Wu Shiqi,Xu Xi,Qiu Zhixia,Li Zhiyu,Wu Hongxi,Bian Jinlei^ORCID,Wang Jubo

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference41 articles.

1. Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials;Panagiotou;Clin. Transl. Oncol.,2022

2. Recent development of CDK inhibitors: an overview of CDK/inhibitor co-crystal structures;Cheng;Eur. J. Med. Chem.,2019

3. Transcriptional addiction in cancer;Bradner;Cell,2017

4. Targeting transcription cycles in cancer;Vervoort;Nat. Rev. Cancer,2022

5. Addressing transcriptional dysregulation in cancer through CDK9 inhibition;Toure;Biochemistry,2023

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application and challenges of nitrogen heterocycles in PROTAC linker;European Journal of Medicinal Chemistry;2024-07

2. Discovery of novel co-degradation CK1α and CDK7/9 PROTACs with p53 activation for treating acute myeloid leukemia;Bioorganic Chemistry;2024-06

3. PROTACs in Ovarian Cancer: Current Advancements and Future Perspectives;International Journal of Molecular Sciences;2024-05-07

4. Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications;Journal of Medicinal Chemistry;2024-04-02

5. Characteristic roadmap of linker governs the rational design of PROTACs;Acta Pharmaceutica Sinica B;2024-04